Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 16/20 | 0.77 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | PKLR | P30613 | 1/20 | 0.59 |
| ▸ | TDP2 | O95551 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9024780 | 0.92 | KIF11 (0.67) | KIF11PKMPKLRTDP2 | |
| SCHEMBL1396616 | 0.87 | KIF11 (1.00) | KIF11PKMPKLRTDP2NPC1 | |
| SCHEMBL31492431 | 0.86 | TDP2 (0.66) | KIF11TDP2 | |
| SCHEMBL30806264 | 0.86 | KIF11 (0.62) | KIF11PKMPKLRTDP2NPC1 | |
| SCHEMBL578303 | 0.86 | TDP2 (0.66) | KIF11TDP2 | |
| SCHEMBL3315694 | 0.85 | KIF11 (0.79) | KIF11PKMPKLR | |
| SCHEMBL16208473 | 0.83 | KIF11 (0.68) | KIF11PKMPKLRNPC1MAPK13 | |
| SCHEMBL16208488 | 0.83 | KIF11 (1.00) | KIF11PKMPKLR | |
| SCHEMBL14868062 | 0.83 | KIF11 (0.71) | KIF11PKMPKLRTDP2 | |
| SCHEMBL761117 | 0.82 | KIF11 (0.68) | KIF11PKMNPC1MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112262145-B | 2-aminopyrimidine derivative and preparation method and application thereof | 上海奕拓医药科技有限责任公司 | 2023-08-01 | — | — | CN | disclosed |
| US-20210253595-A1 | 2-Aminopyrimidine Derivative and Preparation Method and Use Thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
| US-20210253595-A1 | 2-Aminopyrimidine Derivative and Preparation Method and Use Thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
| EP-3786166-A1 | 2-AMINOPYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2021-03-03 | — | — | EP | disclosed |
| EP-3786166-A1 | 2-AMINOPYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2021-03-03 | — | — | EP | disclosed |
| CN-112262145-A | 2-aminopyrimidine derivatives, preparation method and application thereof | 上海奕拓医药科技有限责任公司 | 2021-01-22 | — | — | CN | disclosed |
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2361910-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | KIF11 4379/4885PKM 3697/4885PKLR 3795/4885 |
| US-20210253595-A1 | 2-Aminopyrimidine Derivative and Preparation Method and Use Thereof | IDH1, IDH2, IDH3B | KIF11 3797/4885PKM 1341/4885PKLR 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.